Line Plot from Scientific Research

Plots represent PCSM cumulative incidence in all patients with metastatic disease (A, B); patients treated with SOC-ADT (C, D); patients treated with SOC-ADT plus a docetaxel-containing regimen (E, F); and patients treated with SOC-ADT plus an abiraterone-containing regimen (G, H). Results are stratified by MMAI score quartiles (A, C, E, G) or by fourth quartile versus first three quartiles (B, D, F, H). Shaded regions represent 95% CIs. At-risk and censored patients are shown below plots. Cumulative incidence estimates were compared using Gray’s test. p values lower than 005 were considered significant. ADT=androgen deprivation therapy. MMAI=multimodal artificial intelligence. PCSM=prostate cancer-specific mortality (as defined by the STAMPEDE trial protocol; appendix 2, p 30). SOC=standard-of-care treatment.

DOI